Devonian Health Group Inc. (DVHGF)
USD 0.13
(-6.29%)
USD 0.13
(-6.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.93 Million CAD | -7.22% |
| 2022 | 5.31 Million CAD | -25.0% |
| 2021 | 7.08 Million CAD | -3.11% |
| 2020 | 7.31 Million CAD | 3.41% |
| 2019 | 7.07 Million CAD | 10.1% |
| 2018 | 6.42 Million CAD | 90.57% |
| 2017 | 3.37 Million CAD | -43.33% |
| 2016 | 5.94 Million CAD | 20133.76% |
| 2015 | 29.39 Thousand CAD | -37.02% |
| 2014 | 46.67 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.96 Million CAD | 0.78% |
| 2024 Q2 | 4.06 Million CAD | -18.09% |
| 2024 Q3 | 11.99 Million CAD | 194.84% |
| 2023 Q1 | 4.56 Million CAD | -14.16% |
| 2023 Q2 | 4.54 Million CAD | -0.27% |
| 2023 FY | 4.93 Million CAD | -7.22% |
| 2023 Q3 | 4.9 Million CAD | 7.94% |
| 2023 Q4 | 4.93 Million CAD | 0.41% |
| 2022 Q2 | 6.89 Million CAD | -2.19% |
| 2022 Q4 | 5.31 Million CAD | -16.54% |
| 2022 FY | 5.31 Million CAD | -25.0% |
| 2022 Q1 | 7.05 Million CAD | -0.46% |
| 2022 Q3 | 6.36 Million CAD | -7.69% |
| 2021 Q1 | 6.95 Million CAD | -4.86% |
| 2021 FY | 7.08 Million CAD | -3.11% |
| 2021 Q4 | 7.08 Million CAD | 5.87% |
| 2021 Q3 | 6.69 Million CAD | -1.59% |
| 2021 Q2 | 6.79 Million CAD | -2.27% |
| 2020 Q3 | 8.17 Million CAD | -0.64% |
| 2020 Q4 | 7.31 Million CAD | -10.51% |
| 2020 Q2 | 8.22 Million CAD | 1.23% |
| 2020 FY | 7.31 Million CAD | 3.41% |
| 2020 Q1 | 8.12 Million CAD | 14.88% |
| 2019 Q4 | 7.07 Million CAD | -0.55% |
| 2019 Q2 | 8.6 Million CAD | 10.86% |
| 2019 FY | 7.07 Million CAD | 10.1% |
| 2019 Q1 | 7.76 Million CAD | 20.89% |
| 2019 Q3 | 7.11 Million CAD | -17.39% |
| 2018 Q3 | 6.5 Million CAD | 88.44% |
| 2018 Q4 | 6.42 Million CAD | -1.31% |
| 2018 FY | 6.42 Million CAD | 90.57% |
| 2018 Q2 | 3.45 Million CAD | 1.83% |
| 2018 Q1 | 3.39 Million CAD | 0.63% |
| 2017 FY | 3.37 Million CAD | -43.33% |
| 2017 Q4 | 3.37 Million CAD | -43.31% |
| 2017 Q3 | 5.94 Million CAD | 8888.23% |
| 2017 Q1 | 36.78 Thousand CAD | 4.03% |
| 2017 Q2 | 66.13 Thousand CAD | 79.78% |
| 2016 Q3 | 75.63 Thousand CAD | 109.3% |
| 2016 FY | 5.94 Million CAD | 20133.76% |
| 2016 Q2 | 36.13 Thousand CAD | 22.95% |
| 2016 Q1 | 29.39 Thousand CAD | 0.0% |
| 2016 Q4 | 35.36 Thousand CAD | -53.25% |
| 2015 Q1 | 11.07 Thousand CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 FY | 29.39 Thousand CAD | -37.02% |
| 2015 Q4 | 29.39 Thousand CAD | 0.0% |
| 2014 FY | 46.67 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -28.8% |
| CSL Limited | 18.62 Billion USD | 99.974% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 90.751% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 48.549% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1069.45% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 93.197% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 91.646% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -28.005% |
| Mesoblast Limited | 188.44 Million USD | 97.384% |
| Marizyme, Inc. | 26.67 Million USD | 81.519% |
| Genus plc | 485 Million USD | 98.983% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 15.62% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -95.921% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -29.738% |
| ContraFect Corporation | 32.53 Million USD | 84.845% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -148.827% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.93 Million USD | 87.003% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 58.143% |
| MultiCell Technologies, Inc. | 1617.67 USD | -304660.922% |
| Accustem Sciences Inc. | 1.07 Million USD | -356.806% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 93.632% |
| EV Biologics, Inc. | 2.11 Million USD | -133.091% |
| Q BioMed Inc. | 8.13 Million USD | 39.382% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 94.056% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 4.198% |
| Biomind Labs Inc. | 1.49 Million USD | -228.973% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 73.211% |
| Skye Bioscience, Inc. | 14.07 Million USD | 64.966% |
| SQZ Biotechnologies Company | 50.03 Million USD | 90.148% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3369.528% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 47.918% |
| Intellipharmaceutics International Inc. | 12 Million USD | 58.946% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2351.335% |
| Neon Bloom, Inc. | 1.22 Million USD | -302.053% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 97.98% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -145.259% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 14.198% |
| GB Sciences, Inc. | 5.41 Million USD | 8.999% |
| Alpha Cognition Inc. | 7.16 Million USD | 31.191% |
| argenx SE | 444.95 Million USD | 98.892% |
| HST Global, Inc. | 593.59 Thousand USD | -730.54% |
| Halberd Corporation | 728.71 Thousand USD | -576.533% |
| Enzolytics Inc. | 365.26 Million USD | 98.65% |
| Resverlogix Corp. | 67.39 Million USD | 92.685% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -487.795% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.42% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.847% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -187.633% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 45.478% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 80.078% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -243.829% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 58.582% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -34.51% |
| AVAX Technologies, Inc. | 3.99 Million USD | -23.444% |
| ONE Bio Corp. | 27.49 Million USD | 82.07% |
| Zenith Capital Corp. | 27.56 Thousand USD | -17782.498% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.628% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1965.763% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -32.02% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -624.116% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -81.81% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -291.523% |
| Agentix Corp. | 2.51 Million USD | -96.372% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 3.5 Million USD | -40.662% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -7266.054% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 90.192% |
| BioStem Technologies, Inc. | 15.9 Million USD | 69.003% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -960.907% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -17871.152% |
| LadRx Corporation | 2.2 Million USD | -124.038% |
| Cell Source, Inc. | 15.8 Million USD | 68.811% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -10930.128% |
| Regen BioPharma, Inc. | 5.45 Million USD | 9.667% |
| Regen BioPharma, Inc. | 5.45 Million USD | 9.667% |
| NovAccess Global Inc. | 7.86 Million USD | 37.283% |
| Affymax, Inc. | 8.87 Million USD | 44.425% |
| Itoco Inc. | 1.65 Million USD | -198.22% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -140.306% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 18.498% |
| CytoDyn Inc. | 127.89 Million USD | 96.145% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -11694.603% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -214.741% |
| Qrons Inc. | 1.48 Million USD | -231.16% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 55.365% |
| SYBLEU INC | 681.41 Thousand USD | -623.5% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -509.553% |
| Rebus Holdings, Inc. | 5.24 Million USD | 5.951% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 19.205% |
| Mobile Lads Corp. | 1.31 Million USD | -275.336% |
| International Stem Cell Corporation | 5.27 Million USD | 6.575% |
| Bioxytran, Inc. | 3.24 Million USD | -51.716% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -687.784% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -6.777% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 87.974% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 77.858% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -143.412% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 10.003% |
| Neutra Corp. | 973.52 Thousand USD | -406.408% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 83.009% |
| PureTech Health plc | 125.58 Million USD | 96.074% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -31.218% |
| IXICO plc | 1.9 Million USD | -159.435% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 75.985% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.229% |
| CSL Limited | 18.62 Billion USD | 99.974% |
| Cellectis S.A. | 249.36 Million USD | 98.023% |